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Background: Placental growth factor (PlGF), pregnancy-associated plasma protein-A (PAPP-A), soluble receptor
for advanced glycation end products (sRAGE), extracellular newly identified receptor for RAGE binding protein
(EN-RAGE) and high mobility group box 1 (HMGB-1) are novel biomarkers in chronic kidney disease (CKD).
However, their clinical significance in acute kidney injury (AKI) is unknown. The aim of this cross-sectional study
was to determine whether selected biomarkers are changed in AKI patients.
Methods: Serum PlGF, PAPP-A, sRAGE, EN-RAGE and HMGB-1 levels were assessed in 40 patients with AKI, 42
CKD 5 patients, 31 haemodialysis patients (HD) and 39 age-matched healthy controls.
Results: PAPP-A was elevated in AKI (20.6 ± 16.9 mIU/L) compared with controls (9.1 ± 2.3 mIU/L, p < 0.001). PlGF
was not increased in AKI (11.7 ± 7.4 pg/mL) versus controls (8.5 ± 2.4 pg/mL, n.s.), as well as sRAGE was not
elevated in AKI (2400 ± 1400 pg/mL) compared with controls (1760 ± 730 pg/mL, n.s), but was lower compared
with CKD 5 (3200 ± 1500 pg/mL, p < 0.05); EN-RAGE was elevated in AKI 480 ± 450 ng/mL in comparison with
controls (60 ± 62 ng/mL), CKD 5 (190 ± 120 ng/mL), and HD (120 ± 100 ng/mL), all p < 0.001. Similarly, HMGB-1
was increased in AKI (5.8 ± 7.5 ng/mL) versus controls (1.7 ± 1.4 ng/mL), CKD 5 (3.2 ± 3.1 ng/mL) and HD
(2.5 ±2.1 ng/mL), all p < 0.001.
In AKI group, in multivariate regression analysis: PAPP–A levels were associated with transferrin (p <0.001),
negatively with albumin (p < 0.01) and prealbumin (p < 0.05); PlGF levels were associated with C - reactive
protein (p < 0.001). EN-RAGE levels were associated with ferritin (p < 0.01) and orosomucoid (p = 0.02), and
HMGB-1 levels with leukocyte count (p < 0.01) and negatively with proteinuria (p = 0.02).
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Conclusions: In AKI patients, PAPP-A, EN-RAGE and HMGB1 are elevated, but sRAGE and PlGF are not increased.
Whereas PAPP-A correlates with markers of nutrition; PlGF, EN-RAGE and HMGB-1 are related to inflammatory
parameters.
Keywords: Acute kidney injury, Biomarkers, Chronic kidney disease, Extracellular newly identified receptor for
advanced glycation end products binding protein, Haemodialysis, Placental growth factor, Pregnancy-associated
plasma protein-A, Soluble receptor for advanced glycation end productsBackground
Acute kidney injury (AKI) is associated with substantial
morbidity, mortality and health resource utilization [1,2].
AKI is also increasingly recognized as a prelude to chronic
kidney disease (CKD) [3]. Thus, detection of patients at
particular risk for death, prolonged kidney failure and
associated morbidity after AKI in the setting of renal
replacement therapy (RRT) remains an area of utmost
interest. In addition, early identification of those likely to
progress to CKD and to end stage renal disease (ESRD)
and its associated cardiovascular disease (CVD) morbidity
and mortality has become increasingly important. There-
fore, novel validated biomarkers are required for AKI,
CKD progression and associated CVD risk.
Placental growth factor (PlGF), which is a member of
the vascular endothelial growth factor (VEGF), stimu-
lates angiogenesis and growth of collateral vessels in
ischemic tissues via VEGF receptor-1 (Flt1) [4,5]. PlGF is
upregulated in atheromatic lesions, and antiFlt1 sup-
presses atherosclerotic process and plaque vulnerability
[5]. Recent studies have reported that elevated levels of
circulating PlGF might be associated with worsening
atherosclerosis in patients with decreased renal function
[6,7]. These findings have suggested that PlGF might act
as an inflammatory instigator of atherosclerotic process
in patients with renal impairment.
Pregnancy associated plasma protein-A (PAPP-A) is a
high-molecular-weight zinc-binding metalloproteinase
belonging to metzincin superfamily of metalloprotein-
ases and was originally identified in the plasma of preg-
nant women [8,9]. PAPP-A was found to be abundantly
expressed in eroded and ruptured vascular plaques, but
is only minimally expressed in stable plaques [10]. High
serum levels have been observed in patients with acute
coronary syndromes [10]. PAPP-A levels are elevated in
chronic haemodialysis (HD) patients and have been
identified as an independent mortality predictor in long-
term hemodialysis patients [11].
The receptor for advanced glycation end products
(RAGE) is a member of immunoglobulin superfamily
and is implicated in the pathogenesis of many diseases
including vascular disease, diabetic complications or
inflammatory diseases [12,13]. Advanced glycation end
products and other RAGE ligands accumulate in renalfailure [14]. These compounds are currently considered as
likely players in atherosclerosis in patients with chronic
kidney disease [15]. RAGE exists in several variants. A C-
truncated variant, also known as soluble RAGE (sRAGE),
is a naturally inhibitor of the ligand –RAGE interaction
[16]. Serum sRAGE levels increase in patients with de-
creased renal function [14,16], and an inverse link between
sRAGE and plaque burden in CKD have been reported
[17] implicating the RAGE pathway in vascular damage in
patients with decreased renal function.
The extracellular newly identified RAGE binding protein
(EN-RAGE), also known as calcium binding protein
S100A12, is a ligand for RAGE that is expressed on mac-
rophages, lymphocytes and the endothelium. Binding of
S100A12 to RAGE activates the proinflammatory response
and is overexpressed at sites of local inflammation [18]. In
patients with renal disease a relation of EN-RAGE levels
to markers of inflammation was found [19]. In addition, it
was suggested that elevated EN-RAGE and sRAGE levels
have opposite associations with inflammation in prevalent
HD patients [20].
High mobility group box-1 (HMGB-1) is a 30-kDa nu-
clear and cytosolic ubiquitous protein, a DNA – binding
protein, known as a transcription and growth factor [21].
It has been implicated as a putative danger signal involved
in the pathogenesis of a variety of inflammatory conditions
[22]. HMGB-1 has been reported to trigger cellular signal-
ing through toll-like receptor (TLR) 2, TLR4, and TLR9
and receptor for advanced glycation end products, leading
to the recruitment of inflammatory cells and the release of
proinflammatory cytokines and chemokines that cause
organ damage [13,23,24]. Extracellular HMGB-1 is also in-
volved in the progression of several inflammatory diseases,
including septic shock [25], as well as chronic inflamma-
tory diseases such as rheumatoid arthritis [26] and athero-
sclerosis [27]. More recent study in animal models
demonstrated that HMGB-1 is an early mediator of kidney
ischemia reperfusion injury [28]. Moreover, the only study
in CKD patients has shown that HMGB-1 correlates with
renal function as well as markers of inflammation and
malnutrition in CKD patients [29].
In study presented here, we tested the hypothesis that the
circulating PlGF, PAPP-A, sRAGE, EN-RAGE and HMGB-1
in patients with AKI are altered and might serve as
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of the studied biomarkers specifically their possible relation-
ship to inflammation, nutrition and other parameters, whose
associations are biologically plausible in AKI patients.Methods
Subjects
This cross-sectional, single-centre study at the Department
of Nephrology, First Faculty of Medicine, Charles University
in Prague and General University Hospital in Prague,
Prague, Czech Republic enrolled forty AKI patients at the
inception of renal replacement therapy (RRT). Forty two
patients with CKD 5 at the onset of RRT, thirty one long-
term HD and thirty nine age-matched healthy control
subjects served for comparison.
Written informed consent and laboratory samples were
obtained from all subjects according to ethical guidelines.
The study was approved by the local Institutional Ethical
Committee.
Demographic and biochemical characteristics of the
studied groups are presented in Table 1.
AKI was determined using the RIFLE (Risk, Injury, Fail-
ure, Loss, and End stage kidney) staging criteria for changesTable 1 Clinical and laboratory data of control subjects, AKI,
Variable AKI CKD5
Number of patients (M/F) 22/18 24/18
Age, years 58 ± 17 59 ± 13
BMI, kg/m2 28.3 ± 6.7 28.6 ± 6.9
PlGF, pg/mL 11.7 ± 7.4 12.3 ± 12
PAPP-A, mIU/L 20.0 ± 16.9 20.2 ± 28
sRAGE, pg/mL 2400 ± 1400 3200 ± 15
EN-RAGE, ng/mL 480 ± 450 190 ± 12
HMGB-1, ng/mL 5.8 ± 7.5 3.2 ± 3.1
BUN, mmol/L 29 ± 13 27.1 ± 7.8
Creatinine, μmol/L 593 ±272 520 ± 14
Albumin, g/L 30.1 ± 7.0 35.5 ± 7.1
Prealbumin, g/L 0.2 ± 0.1 0.26 ± 0.1
CRP, mg/L 60 ± 70 19 ± 22
Fibrinogen, g/L 5.2 ± 1.9 5.2 ± 1.4
Orosomucoid, g /L 1.6 ± 0.67 1.38 ± 0.4
Hemoglobin, g/L 101 ± 22 102 ± 19
Leukocytes x109 10.7 ± 5.3 8.5 ± 3.5
Proteinuria g/ 24 hours 2.5 ± 3.8 2.8 ± 3.4
Residual diuresis, L/ 24 hours 1.9 ± 1.3 1.8 ± 1.0
GFR, mL/s/1.73 m2 0.18 ± 0.18 0.18 ± 0.0
Data are expressed as mean ± SD and analysed using ANOVA.
aSome results of HD patients were presented previously [7,19].
bMeasured in 27 control subjects.
Abbreviations: AKI acute kidney injury, CKD5 chronic kidney disease stage 5, BMI body m
M male, sRAGE soluble receptor for advanced glycation end products, EN-RAGE extracel
protein, HD haemodialysis, HMGB-1 high mobility group box protein-1, PAPP-A pregnancyin the serum creatinine within one week [30]. The enrol-
ment was performed by attending nephrologists prior to
RRT initiation. Further, blood tests and physiological param-
eters were obtained for each patient at the time of admission
to the department after inclusion but before initiation of
RRT. The aetiologies of AKI were ischemia (39.8%), nephro-
toxicity (22%), and multifaceted factors (38.2%). All enrolled
patients with AKI were hemodynamically stable. The pa-
tients on mechanical ventilation were not included. We in-
cluded AKI patients without sepsis. Most patients received
medication used in acute kidney injury including vasoactive
therapy, fluid supplementation before RRT, anticoagulation,
antihypertensive treatment. Eligible patients received empi-
rical antibiotic regimens. Antibiotics were generally dosed as
recommended in the corresponding package inserts. The
dose of antibiotics was adjusted according to patients’ condi-
tions and creatinine clearance.
Forty patients with CKD stage 5 with glomerular filtra-
tion rate (eGFR < 15 ml/min/1.73 m2) at the onset of RRT
were included. The aetiology of CKD were vasculits (11%),
chronic glomerulonephritis (23%) hypertension (19%) and
diabetes (12%). The CKD patients were in stable clinical
status, without signs of overt inflammation. Most patients
received medications commonly used in patients withCKD 5 and HD patients
aHD Controls pANOVA
15/16 14/25
59 ± 16 57 ± 10 0.87
24.3 ± 4.1 25.2 ± 3.4 <0.001
.4 11.5 ± 3.8 8.5 ± 2.4 0.02
.1 20.8 ± 10.1 9.1 ± 2.3 <0.006
00 2700 ± 1200 1760 ± 730 <0.0001
0 120 ± 100 60 ± 62 <0.0001
2.5 ± 2.1 b1.7 ± 1.4 <0.0001
26.4 ± 7.5 4.9 ± 1.2 <0.0001
0 800 ± 210 86 ± 12 <0.0001
40.7 ± 3.3 43.6 ± 2.4 0.0001
1 0.32 ± 0.7 0.26 ± 0.02 <0.0001
12 ± 16 3.2 ± 2.1 <0.0001
4.8 ± 1.4 3.35 ± 057 0.002
7 1.7 ± 0.38 0.78 ± 0.19 <0.001
108 ± 10 141 ± 10 0.001
7.5 ± 2.5 6.3 ± 1.8 <0.001
– –
0.67 ± 0.70 – <0.0001
9 0.11 ± 0.05 1.26 ± 3.0 <0.0001
ass index, BUN blood urea nitrogen, CRP C-reactive protein, F female,
lular newly identified receptor for advanced glycation end products binding
-associated plasma protein-A, SD standard deviation, GFR glomerular filtration rate.
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vitamin D supplements; statins; and antihypertensive drugs.
Thirty one patients on maintenance haemodialysis, who
had been treated at least three months, were included.
Underlying renal diseases were diabetic nephropathy
(12%), hypertensive nephrosclerosis (15%), polycystic dis-
ease (22%), interstitial nephritis (16%) and unknown aeti-
ology (22%). All HD patients were receiving conventional
4-hour dialysis treatment 3 times a week with standard bi-
carbonate dialysis solution with heparin as anticoagulant.
The average dose of dialysis (Kt/V) was 1.46 ± 0.2. The
majority of patients were treated with antihypertensive
medication and 45% were also treated with statins for dys-
lipidemia. The HD patients were in stable clinical status,
without signs of overt inflammation. The detailed patients’
characteristics were published previously [7,19].
The control group consisted of thirty nine age matched
healthy subjects. They were not administered any special
alimentary supplements at the time of the study.Blood samples
In AKI and CKD 5 groups, blood was collected prior to
the first dialysis session and prior to heparin administra-
tion. In HD patients, blood was collected via puncture of
the arteriovenous fistula before starting the dialysis session
and prior to heparin administration. In other subjects,
blood was collected after overnight fasting via puncture of
the cubital vein, simultaneously with blood collection for
routine control examinations.
Blood count and routine biochemical parameters were
determined in fresh samples. For special biochemical
analyses, blood was centrifuged for 10 min at 1,450 g,
and serum was frozen at −80°C until analysis. All sera
were analyzed within one year.
Laboratory parameters
PlGF was measured by means of sandwich ELISA (en-
zyme-linked immunosorbent assay) using standard kits
(R&D Systems, Inc., Minneapolis, MN, USA) according to
the manufacturer’s protocol. Results are given in pico-
grams per milliliter (pg/mL).
PAPP-A was assessed immunochemically with TRACE
(Time Resolved Amplified Cryptate Emission) by the
KRYPTOR analyzer (Thermo Fischer, Henningsdorf,
Germany). The results are expressed in mIU/L.
sRAGE was measured using a commercially avail-
able sandwich ELISA kit according to the instructions
of the manufacturer (Quantikine; R&D Systems, Inc.,
Minneapolis, MN, USA). Results are given in pico-
grams per milliliter (pg/mL).
EN-RAGE was measured by means of a sandwich
ELISA using standard kits (Circulex™, CycLex Co. Ltd.,
Nagano, Japan) according to the manufacturer’sprotocol. Results are given in nanograms per milliliter
(ng/mL).
HMGB-1 was measured using a commercially available
sandwich ELISA kit according to the instructions of
the manufacturer (IBL International GmbH, Hamburg,
Germany). Results are given in picograms per milliliter
(pg/mL).
C-reactive protein (CRP) and prealbumin were determined
turbidimetrically, orosomucoid (acidic α1-glycoprotein) and
alpha-2 Macroglobulin were assessed nephelometri-
cally and fibrinogen was measured by the trombin
method. Albumin was determined by photometry with
bromcresole green. Routine biochemical parameters
and blood count were assessed using standard labora-
tory methods with automated analyzers. The eGFR
was calculated using the MDRD formula [31].
Statistical analysis
Statistical analyses were performed using Statistics
Toolbox™ MATLAB® software (The MathWorks™, Inc.,
Natick, Massachusetts, USA). Data are presented as
the mean ± SD for continuous variables and percen-
tages for categorical variables. Univariate comparisons
of continuous variables between control subjects and
renal disease patients were conducted with unpaired
sample t-tests; and ANOVA with post tests for nor-
mally distributed continuous variables. Mann–Whitney
U test and Kruskal-Wallis ANOVA with Tukey-Kramer
or Dunn's post tests for non-normal distributions was
used to compare continuous variables between control
subjects and renal patients. Variables with non-normal
distributions were log-transformed where appropriate.
Association among analyzed parameters was assessed
using Spearman’s or Pearson’s correlation coefficient.
Stepwise multivariate regression analysis was used to assess
independent predictors of studied biomarkers. All results
were considered statistically significant at p < 0.05.
Results
Serum PlGF, PAPP-A, sRAGE, EN-RAGE, and HMGB-1
determined from blood obtained in AKI, CKD 5, HD and
control groups are displayed at Table 1. PlGF was not in-
creased in AKI (11.7 ± 7.4 pg/mL) compared with controls
(8.5 ± 2.4 pg/mL, n.s.), but was elevated (p < 0.05) in HD
(11.5 ± 3.8 pg/mL, p < 0.05) versus controls (Figure 1).
PAPP-A was elevated in AKI (20.0 ± 16.9 mIU/L) CKD 5
(20.2 ± 28.1 mIU/L) and HD (20.8 ± 10.1 mIU/L) com-
pared with controls (9.1 ± 2.3 mIU/L, p < 0.001) (Figure 2).
sRAGE was not elevated in AKI (2400 ± 1400 pg/mL)
compared with controls (1760 ± 730 pg/mL, n.s), but was
lower compared with CKD 5 (3200 ± 1500 pg/mL, p <
0.05). sRAGE was increased in CKD 5 (3200 ± 1500 pg/
mL) and HD (2700 ± 1200 pg/mL) versus controls
(Figure 3). EN-RAGE was elevated in AKI (480 ±
Figure 1 Serum PlGF levels in AKI, CKD 5, HD and healthy controls. Data are expressed as mean ± SD and analysed using ANOVA. Post-tests
(Tukey-Kramer test or Dunn’s multiple comparison test).
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CKD 5 (190 ± 120 ng/mL), and HD (120 ± 100 ng/mL), all
p < 0.001 (Figure 4). Similarly, HMGB-1 was increased in
AKI (5.8 ± 7.5 ng/mL) versus controls (1.7 ± 1.4 ng/mL),
CKD 5 (3.2 ± 3.1 ng/mL) and HD (2.5 ±2.1 ng/mL), all
p < 0.001, as well as HMGB-1 was higher in CKD 5 and
HD in comparison with controls (Figure 5).
The results of univariate correlations between PlGF,
PAPP-A, sRAGE, EN-RAGE, HMGB-1 and other vari-
ables in AKI patients and other studied groups were
shown at Table 2. In AKI group, sRAGE levels were in-
versely correlated with haemoglobin (r = − 0.44, p = 0.001).
In multivariate regression analysis: PAPP–A levels were
associated with transferrin (p <0.001), negatively with
albumin (p < 0.01) and prealbumin (p < 0.05); PlGF levels
were associated with C - reactive protein (p < 0.001). EN-
RAGE levels were associated with ferritin (p < 0.01) andFigure 2 Serum PAPP-A levels in AKI, CKD 5, HD and healthy controls
Post-tests (Tukey-Kramer test or Dunn’s multiple comparison test).orosomucoid (p = 0.02), and HMGB-1 levels with leukocyte
count (p < 0.01) and negatively with proteinuria (p = 0.02)
(Table 3).
To conclude the PAPP-A, EN-RAGE and HMGB-1
levels are significantly elevated, but sRAGE and PlGF
levels are not increased in AKI patients. sRAGE has a
reverse relation to haemoglobin. PAPP-A levels are inde-
pendently associated with markers of nutrition: trans-
ferin and negatively with albumin and prealbumin. PlGF
is associated with CRP. EN-RAGE is independently asso-
ciated with inflammatory markers: ferritin and orosomu-
coid. HMGB-1 is associated with leukocyte count and
negatively with proteinuria in AKI patients.
Discussion
This is the first study where we demonstrate the circu-
lating levels of PLGF, PAPP-A, sRAGE, EN-RAGE and. Data are expressed as mean ± SD and analysed using ANOVA.
Figure 3 Serum sRAGE levels in AKI, CKD 5, HD and healthy controls. Data are expressed as mean ± SD and analysed using ANOVA. Post-
tests (Tukey-Kramer test or Dunn’s multiple comparison test).
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Significantly higher levels of PAPP-A, EN-RAGE and
HMGB-1, but not increased levels of sRAGE and PlGF
were observed in the serum of patients with AKI as
compared with controls. Further, this study demon-
strates significant independent associations of PAPP-A
with markers of nutrition, and the associations of PlGF,
EN-RAGE, and HMGB-1 with inflammatory parameters
in these patients for the first time.
Although PlGF levels in AKI patients were not ele-
vated, PlGF was significantly correlated with inflamma-
tory markers CRP and fibrinogen and inversely with a
negative inflammatory marker prealbumin. However,
only CRP was positively associated with PlGF levels by
multivariate analysis. CRP is a short pentraxin and an
established biomarker of inflammation in kidney disease
[32]. A recent study has suggested that the level of theFigure 4 Serum EN-RAGE levels in AKI, CKD 5, HD and healthy contro
Post-tests (Tukey-Kramer test or Dunn’s multiple comparison test).ratio of CRP to prealbumin was associated with mortal-
ity of AKI patients [33]. Moreover, lower serum prealbu-
min levels were strongly associated with a higher risk of
death independent of AKI severity [34]. On the other
hand, serum fibrinogen is independently predictive of
cardiovascular and all-cause mortality in end-stage kid-
ney disease [35] and in patients with CKD [36]. In AKI
serum fibrinogen levels were comparable with those
found in healthy controls [37]. It is thus conceivable that
PlGF is released from endothelial cells, among others, in
response to inflammation in AKI.
PAPP-A levels were increased in AKI patients in com-
parison with healthy controls, but were comparable to
those found in CKD 5 and HD patients. In line with pre-
vious report, PAPP-A is elevated in HD patients [38] and
is a prognostic marker in dialysis patients [11]. The PAPP-A
levels were also significantly decreased in dialysis patientsls. Data are expressed as mean ± SD and analysed using ANOVA.
Figure 5 Serum HMGB1 levels in AKI, CKD 5, HD and healthy controls. Data are expressed as mean ± SD and analysed using ANOVA.
Post-tests (Tukey-Kramer test or Dunn’s multiple comparison test).
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than in control group [39]. The mechanisms of PAPP-A
increase most probably include the increased synthesis,
but also the decreased clearance of PAPP-A in patients
with decreased renal function, including the patients with
AKI. In this study, PAPP-A levels were independently as-
sociated with markers of nutrition: transferin and nega-
tively with albumin and prealbumin. These results permit
the conclusion that PAPP-A levels are elevated in pa-
tients with AKI and related to markers of nutrition, but
are not related to inflammatory markers, as in HD pa-
tients in this and previous studies [40].
We provide here evidence that sRAGE levels are
increased but not significantly in the setting of AKI. An
explanation for the comparable sRAGE levels in AKI might
be an enhanced consumption of this molecule. sRAGE acts
as an anti-inflammatory “decoy” by binding and preventing
their interaction with cell surface RAGE, suppresses the
RAGE mediated inflammatory response [16]. The ligands
EN-RAGE and HMGB-1 binding to sRAGE might influ-
ence the levels of sRAGE and increase the propensity
towards inflammation. RAGE ligands therefore have better
binding across to cell membrane receptor, the binding of
which activates the inflammatory pathways. Interestingly,
in a recent study in septic AKI patients sRAGE levels were
elevated [41]. In CKD and HD patients serum sRAGE
levels were also increased in this and the previous study
and was inversely related to inflammation [42]. The correl-
ation revealed in our AKI patients between serum sRAGE
levels and declining haemoglobin suggest that reduced
tissue oxygenation associated with anaemia may contribute
to the formation of AGEs and activation of RAGE with
possible toxic effect of them on haematopoiesis, while
sRAGE might inhibit their pathological effect. We cannot
also exclude the effect of amelioration of endothelial and
inflammatory injuries on the serum sRAGE activity in AKI.sRAGE levels in AKI, similarly as in CKD and HD, could
be an indicator of enhanced RAGE expression as counter-
regulatory system against endothelial damage i.e. inflam-
mation and oxidative stress. Given the importance of
anaemia in decreased renal function, the association
between sRAGE and anaemia in AKI patients deserves
further studies.
In the present study, EN-RAGE levels were significantly
increased in AKI patients, but not in CKD5 and HD
patients. These results are in line with our previous study
where the serum concentrations of CKD patients and HD
were not elevated in comparison with healthy controls
[19]. Similarly as in CKD, HD and peritoneal dialysis
patients [19,43], also in AKI patients a relation of serum
EN-RAGE levels to markers of inflammation was found.
Specifically, EN-RAGE concentrations were independently
associated with orosomucoid and ferrtitin.
Plasma EN-RAGE triggers the RAGE pathway as proin-
flammatory ligand activating key inflammatory signals
such as NF-κB and MAP kinase and stimulates cell adhe-
sion molecules. Circulating EN-RAGE is associated with
CVD events and CVD-related mortality in HD patients,
which partly explained by its link to inflammation [44],
and is related to mortality of HD patients due to infection
[45]. Orosomucoid, being an acute phase protein, contrib-
utes to immune response in inflammatory states modulat-
ing chemotaxis of neutrophils, superoxide generation and
aggregation [46]. On the other hand, a recent study in a
murine model of acute renal failure has shown that oroso-
mucoid partially restored activity of clotting and comple-
ment systems in acute renal failure [47]. This effect may
be due to accumulation of orosomucoid in renal tissue
and its protective action in situ. Taken together, higher
serum EN-RAGE levels and relation to inflammatory
markers in this study may be associated with amplified in-
flammatory response and vascular damage in AKI patients.
Table 2 Univariate correlations between biomarkers and other variables






r = 0.57, p = 0.002
Fibrinogen,
r = 0.47, p = 0.002 r = 0.34, p = 0.03 r = − 0.41, p = 0.01
Prealbumin,
r = − 0.37, p = 0.02
PAPP-A
Albumin Fibrinogen, Leucocyte count,
Cholesterol,
r = − 0.42, p = 0.01 r = − 0.34, p = 0.03 r = − 0.34, p = 0.03
Transferin, Serum protein, Albumin,
r = 0.36, p = 0.01 r = − 0.38, p = 0.03 r = − 0.038, p = 0.03
Prealbumin BUN, CRP, r = − 0.44, p = 0.01
r = − 0.42, p = 0.01 r = 0.32, p = 0.03 r = 0.4, p = 0.02
Cholesterol,






r = − 0.36, p = 0.03 r = − 0.41, p = 0.01
r = − 0.44, p = 0.001 GFR, r = 0.43, p = 0.02 GFR,






r = 0.36, p = 0.03
Orosomucoid, r = 0.63,. p = 0.001
r = 0.46, p = 0.003 Fibrinogen,
Ferritin, r = 0.49, p = 0.01 r = 0.39, p = 0.02
r = 0.51, p = 0.001 r = 0.38, p = 0.04 CRP, GFR,
Leucocyte count, Age, r = 0.78, p = 0.001 r = 0.33, p = 0.04
r = 0.51, p = 0.03 r = − 0.44, p = 0.04 Orosomucoid, sRAGE,
GFR, r = 0.43, p = 0.001 r = − 0.41, p = 0.01
r = − 0.34, p = 0.04 Leukocyte count,
BUN, r = − 0.56, p = 0.01






r = 0.42, p = 0.01
Proteinuria, r = 0.45, p = 0.01
r = − 0.36, p = 0.02 r = 0.48, p = 0.001 Total protein,
Cholesterol, r = 0.48, p = 0.01
r = − 0.34, p = 0.03
Data are expressed as mean ± SD.
Abbreviations: AKI acute kidney injury, BUN blood urea nitrogen, CKD5 chronic kidney disease stage 5, CRP C-reactive protein, sRAGE soluble receptor for advanced
glycation end products, EN-RAGE extracellular newly identified receptor for advanced glycation end products binding protein, HD haemodialysis, HMGB-1 high mo-
bility group box protein-1, PAPP-A pregnancy-associated plasma protein-A, SD standard deviation, GFR glomerular filtration rate.
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http://www.biomedcentral.com/1471-2369/14/245In the present study all AKI patients in our study had
elevated circulating HMGB-1 levels as compared with
controls. We could also show that HMGB-1 levels were
independently associated with leukocyte count and nega-
tively with proteinuria in AKI setting. Although, we could
not exclude patients with high CRP levels in AKI patients,
in multivariate analysis no relationship to CRP levels were
found. HMGB-1 is one of the high-affinity ligands forRAGE/sRAGE, a potent cytokine playing an important
role in the pathogenesis of inflammation. Previous studies
have shown that HMGB-1 differs from early innate proin-
flammatory cytokines, such as TNF and IL-1, in endoto-
xaemia and sepsis models [25,48]. HMGB-1 release occurs
in response to a number of alarm signals including endo-
toxin, interferons, TNFs and largely is a consequence of
NF-κB activation and HMGB-1 acetylation at its nuclear
Table 3 Associations of PlGF, PAPP-A, EN-RAGE and HMGB-1 levels in AKI patients (multivariate regression analysis)
Predictor B coefficient SE T p Intercept R 2
PlGF CRP 0.0018 0.00043 4.2 0.0001 0.8 0.32
PAPP-A Albumin −0.0153 0.0048 −3.1 0.003 1.6 0.47
Transferrin 0.0674 0.0174 3.8 0.0004
Prealbumin −0.6379 0.3005 −2.1 0.04
EN-RAGE Ferritin 519.26 181.72 2.8 0.006 −955.48 0.35
Orosomucoid 722.37 318.18 2.2 0.02
HMGB-1 Leucocyte count 1.063 0.384 2.7 0.008 −0.537 0.28
Proteinuria/24 hours −0.307 0.128 −2.3 0.02
Abbreviations: CRP C-reactive protein, sRAGE soluble receptor for advanced glycation end products, EN-RAGE extracellular newly identified receptor for advanced
glycation end products binding protein, HMGB-1 high mobility group box protein-1, PAPP-A pregnancy-associated plasma protein-A.
Zakiyanov et al. BMC Nephrology 2013, 14:245 Page 9 of 11
http://www.biomedcentral.com/1471-2369/14/245localization site [49,50]. This induces vesicular sequestra-
tion and leads to extracellular HMGB-1 release [51,52]. In
addition, passive diffusion from necrotic cells might occur
[51,53]. Another interesting finding is the negative associ-
ation of HMGB-1 and proteinuria in AKI setting, support-
ing the concept that HMGB-1 could be a marker of renal
injury in patients with AKI. Whether high HMGB-1 levels
in AKI are the consequences of the disease or a potential
contributing factor to the disease needs to be elucidated.
The most frequent cause of AKI in the Intensive Care
Units is sepsis [54]. Endothelial activation defined as
upregulation of adhesion molecules by proinflammatory
cytokines, may be central to the development of sepsis
induced AKI.
In this study the CKD and HD patients with overt
inflammation were excluded. We endeavored to include a
comparative cohort of AKI patients specifically without
sepsis. Although, we have not included the patients with
sepsis in this study, the association of studied biomarkers
with inflammatory markers support the notion that also in
sepsis induced AKI the levels of studied biomarkers might
be changed. Indeed, pretransplant inflammation including
the elevation of PAPP-A in transplant recipients might
play an important role in the pathogenesis of ischemic
AKI and could be a risk factor for the development of de-
layed graft function [55]. Serum PAPP-A levels frequently
increases in patients with severe sepsis and appears to be
associated with sepsis related myocardial dysfunction [56].
PlGF levels are elevated in preclinical models of sepsis
[57]. PlGF protects liver endothelial cells against septic in-
jury, explaining why sepsis morbidity is increased follow-
ing genetic or pharmacological PlGF blockade [57,58].
sRAGE levels were elevated during acute lung injury,
regardless of the presence or absence of severe sepsis [59].
Also in another study in septic patients an elevation of
sRAGE levels were shown [60]. Non-survivors had higher
plasma sRAGE concentrations than survivors. In addition,
recently also in septic AKI patients sRAGE levels were ele-
vated [41]. In contrast, in a recent study the sRAGE levels
were not changed in severe sepsis, while the EN-RAGEconcentrations were significantly increased in patients
with severe sepsis stratified to the three most common in-
fectious sources (lungs, abdomen, and urinary tract) [61].
In addition, HMGB-1 has been identified as late cytokine
mediator of endotoxaemia and sepsis [52,62,63]. HMGB-1
was persistently elevated in patients with severe sepsis and
severe shock [64]. Taken together, PlGF, PAPP-A, sRAGE,
EN-RAGE and HMGB-1 might play a role also in sepsis
induced AKI. Further studies are warranted to test the
clinical utility of these biomarkers in managing patients
with sepsis and AKI and to better understand their
relationship with kidney morphology during acute kidney
injury.
There are several limitations in this study, including
small sample size of adult patients with severe AKI (RIFLE
category failure). Nevertheless, this is the first study to re-
port an association of studied biomarkers and relevant pa-
rameters in AKI patients. Second, the studied population
was composed by heterogeneous AKI patients treated at
single centre of faculty hospital. Third, we did not com-
pare studied biomarkers with established one such as
neutrophil gelatinase associated lipocalin. Finally, we did
not perform a kinetic study on novel biomarkers including
more frequent sampling.Conclusions
The study presented here provides first insight into
levels of circulating PlGF, PAPP-A, sRAGE, EN-RAGE
and HMGB-1 in patients with AKI. The PAPP-A, EN-
RAGE and HMGB1 levels are significantly elevated, but
sRAGE and PlGF levels are not increased in AKI
patients. Whereas PlGF, EN-RAGE, and HMGB-1 levels
are significantly related to inflammatory markers, PAPP-
A levels are associated with markers of nutrition in AKI
setting. Larger, prospective clinical studies are needed to
confirm the results of our single centre study.Competing interests
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